{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:46:19Z","timestamp":1789785979278,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,12]],"date-time":"2017-03-12T00:00:00Z","timestamp":1489276800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00280-017-3266-0","type":"journal-article","created":{"date-parts":[[2017,3,12]],"date-time":"2017-03-12T11:20:06Z","timestamp":1489317606000},"page":"737-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia"],"prefix":"10.1007","volume":"79","author":[{"given":"Islem","family":"Ben Hassine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanene","family":"Gharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouheb","family":"Teber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlem","family":"Farrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Ben Hadj Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassiba","family":"Amouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Bellaaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayhane Ben","family":"lakhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neila Ben","family":"Romdhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem","family":"Abbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Menif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,12]]},"reference":[{"key":"3266_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.emch.2005.07.001","volume":"2","author":"T Leguay","year":"2005","unstructured":"Leguay T, Mahon F-X (2005) Leuc\u00e9mie my\u00e9lo\u00efde chronique. EMC H\u00e9matologie 2:187\u2013205. doi: 10.1016\/j.emch.2005.07.001","journal-title":"EMC H\u00e9matologie"},{"key":"3266_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R (2005) Mechanisms of BCR\u2013ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5:172\u2013183. doi: 10.1038\/nrc1567","journal-title":"Nat Rev Cancer"},{"key":"3266_CR3","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8:1018\u20131029. doi: 10.1016\/S1470-2045(07)70342-X","journal-title":"Lancet Oncol"},{"key":"3266_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/671702","volume":"2012","author":"G Nestal de Moraes","year":"2012","unstructured":"Nestal de Moraes G, Souza PS, Costas FC de F et al (2012) The interface between BCR-ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia. Leuk Res Treat 2012:1\u201319. doi: 10.1155\/2012\/671702","journal-title":"Leuk Res Treat"},{"key":"3266_CR5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","volume":"17","author":"K Eechoute","year":"2011","unstructured":"Eechoute K, Sparreboom A, Burger H et al (2011) Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 17:406\u2013415. doi: 10.1158\/1078-0432.CCR-10-2250","journal-title":"Clin Cancer Res"},{"key":"3266_CR6","doi-asserted-by":"crossref","unstructured":"Dulucq S, Krajinovic M (2010) The pharmacogenetics of imanitib. Genome Med 2:85.","DOI":"10.1186\/gm206"},{"key":"3266_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697\u2013704. doi: 10.1182\/blood-2005-11-4687","journal-title":"Blood"},{"key":"3266_CR8","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064\u20134072. doi: 10.1182\/blood-2007-06-093617","journal-title":"Blood"},{"key":"3266_CR9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/clpt.2011.12","volume":"89","author":"JR Engler","year":"2011","unstructured":"Engler JR, Hughes TP, White DL (2011) OCT-1 as a determinant of response to antileukemic treatment. Clin Pharmacol Ther 89:608\u2013611. doi: 10.1038\/clpt.2011.12","journal-title":"Clin Pharmacol Ther"},{"key":"3266_CR10","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s00424-003-1089-9","volume":"447","author":"H Koepsell","year":"2004","unstructured":"Koepsell H, Endou H (2004) The SLC22 drug transporter family. Pflugers Arch 447:666\u2013676. doi: 10.1007\/s00424-003-1089-9","journal-title":"Pflugers Arch"},{"key":"3266_CR11","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s11095-007-9254-z","volume":"24","author":"H Koepsell","year":"2007","unstructured":"Koepsell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227\u20131251. doi: 10.1007\/s11095-007-9254-z","journal-title":"Pharm Res"},{"key":"3266_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0851-5","author":"LT Lima de","year":"2014","unstructured":"de Lima LT, Vivona D, Bueno CT et al (2014) Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Med Oncol. doi: 10.1007\/s12032-014-0851-5","journal-title":"Med Oncol"},{"key":"3266_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000336610","volume":"127","author":"L Nardinelli","year":"2012","unstructured":"Nardinelli L, Sanabani SS, Didone A et al (2012) Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia. Acta Haematol 127:228\u2013234. doi: 10.1159\/000336610","journal-title":"Acta Haematol"},{"key":"3266_CR14","doi-asserted-by":"publisher","DOI":"10.3892\/or.2012.2153","author":"M Gromicho","year":"2012","unstructured":"Gromicho M (2012) Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Oncol Rep. doi: 10.3892\/or.2012.2153","journal-title":"Oncol Rep"},{"key":"3266_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/bjh.12591","volume":"163","author":"J Grinfeld","year":"2013","unstructured":"Grinfeld J, Gerrard G, Alikian M et al (2013) A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. Br J Haematol 163:631\u2013639. doi: 10.1111\/bjh.12591","journal-title":"Br J Haematol"},{"key":"3266_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1309\/LMP1ECAE30JSVZEP","volume":"44","author":"S Solali","year":"2013","unstructured":"Solali S, Kaviani S, Movassaghpour AA, Aliparasti MR (2013) Real-time polymerase chain reaction testing for quantitative evaluation of hOCT1 and MDR1 expression in patients with chronic myeloid leukemia resistant to imatinib. Lab Med 44:13\u201319. doi: 10.1309\/LMP1ECAE30JSVZEP","journal-title":"Lab Med"},{"key":"3266_CR17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","volume":"121","author":"A Giannoudis","year":"2013","unstructured":"Giannoudis A, Wang L, Jorgensen AL et al (2013) The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 121:628\u2013637. doi: 10.1182\/blood-2012-01-405035","journal-title":"Blood"},{"key":"3266_CR18","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884. doi: 10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"3266_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1006\/abio.1987.9999","volume":"162","author":"P Chomzynski","year":"1987","unstructured":"Chomzynski P (1987) single-step method of RNA isolation by acid guanidinium thiocyanate\u2013phenol\u2013chloroform extraction. Anal Biochem 162:156\u2013159. doi: 10.1006\/abio.1987.9999","journal-title":"Anal Biochem"},{"key":"3266_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2013\u2206\u2206CT method. Methods 25:402\u2013408. doi: 10.1006\/meth.2001.1262","journal-title":"Methods"},{"issue":"532\u2013534","key":"3266_CR21","first-page":"536","volume":"15","author":"P Chomczynski","year":"1993","unstructured":"Chomczynski P (1993) A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15(532\u2013534):536\u2013537","journal-title":"Biotechniques"},{"key":"3266_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1471-2105-13-134","volume":"13","author":"J Ye","year":"2012","unstructured":"Ye J, Coulouris G, Zaretskaya I et al (2012) Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction. BMC Bioinform 13:134. doi: 10.1186\/1471-2105-13-134","journal-title":"BMC Bioinform"},{"key":"3266_CR23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.cr.7290272","volume":"15","author":"Y Yong","year":"2005","unstructured":"Yong Y, Lin HE (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15:97\u201398","journal-title":"Cell Res"},{"key":"3266_CR24","doi-asserted-by":"publisher","unstructured":"Li Z, Zhang Z, He Z et al (2009) A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis http:\/\/analysis.bio-x.cn . Cell Res 19:519\u2013523. doi: 10.1038\/cr.2009.33","DOI":"10.1038\/cr.2009.33"},{"key":"3266_CR25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/cncr.25527","volume":"117","author":"J Cortes","year":"2011","unstructured":"Cortes J, Quint\u00e1s-Cardama A, Kantarjian HM (2011) Monitoring molecular response in chronic myeloid leukemia. Cancer 117:1113\u20131122. doi: 10.1002\/cncr.25527","journal-title":"Cancer"},{"key":"3266_CR26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","volume":"106","author":"LC Crossman","year":"2005","unstructured":"Crossman LC (2005) hOCT 1 and resistance to imatinib. Blood 106:1133\u20131134. doi: 10.1182\/blood-2005-02-0694","journal-title":"Blood"},{"key":"3266_CR27","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104:3739\u20133745. doi: 10.1182\/blood-2003-12-4276","journal-title":"Blood"},{"key":"3266_CR28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/1078-0432.CCR-13-199929","volume":"20","author":"AT Nies","year":"2014","unstructured":"Nies AT, Schaeffeler E, van der Kuip H et al (2014) Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res Off J Am Assoc. Cancer Res 20:985\u2013994. doi: 10.1158\/1078-0432.CCR-13-199929","journal-title":"Cancer Res"},{"key":"3266_CR29","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","volume":"14","author":"S Hu","year":"2008","unstructured":"Hu S, Franke RM, Filipski KK et al (2008) Interaction of Imatinib with Human Organic Ion Carriers. Clin Cancer Res 14:3141\u20133148. doi: 10.1158\/1078-0432.CCR-07-4913","journal-title":"Clin Cancer Res"},{"key":"3266_CR30","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/leu.2015.170","volume":"29","author":"DB Watkins","year":"2015","unstructured":"Watkins DB, Hughes TP, White DL (2015) OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia 29:1960\u20131969. doi: 10.1038\/leu.2015.170","journal-title":"Leukemia"},{"key":"3266_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","volume":"83","author":"L Wang","year":"2008","unstructured":"Wang L, Giannoudis A, Lane S et al (2008) Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol 38 Ther 83:258\u2013264. doi: 10.1038\/sj.clpt.6100268","journal-title":"Clin Pharmacol"},{"key":"3266_CR32","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381\u20132388. doi: 10.1200\/JCO.2009.26.3087","journal-title":"J Clin Oncol"},{"key":"3266_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12185-011-0924-6","volume":"94","author":"F Razga","year":"2011","unstructured":"Razga F, Racil Z, Machova Polakova K et al (2011) The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia. Int J Hematol 94:303\u2013306. doi: 10.1007\/s12185-011-0924-6","journal-title":"Int J Hematol"},{"key":"3266_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/0971-5916.164250","volume":"142","author":"H Malhotra","year":"2015","unstructured":"Malhotra H, Sharma P, Malhotra B et al (2015) Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase. Indian J Med Res 142:175. doi: 10.4103\/0971-5916.164250","journal-title":"Indian J Med Res"},{"key":"3266_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ajh.21722","volume":"85","author":"Z Racil","year":"2010","unstructured":"Racil Z, Razga F, Buresova L et al (2010) The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. Am J Hematol 85:525\u2013528. doi: 10.1002\/ajh.21722","journal-title":"Am J Hematol"},{"key":"3266_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/ejh.12235","volume":"92","author":"M Koren-Michowitz","year":"2014","unstructured":"Koren-Michowitz M, Buzaglo Z, Ribakovsky E et al (2014) OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. Eur J Haematol 92:283\u2013288. doi: 10.1111\/ejh.12235","journal-title":"Eur J Haematol"},{"key":"3266_CR37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/tpj.2015.78","volume":"15","author":"C Arimany-Nardi","year":"2015","unstructured":"Arimany-Nardi C, Koepsell H, Pastor-Anglada M (2015) Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug\u2013drug interactions. Pharmacogenomics J 15:473\u2013487","journal-title":"Pharmacogenomics J"},{"key":"3266_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejphar.2015.08.034","volume":"765","author":"S Vaidya","year":"2015","unstructured":"Vaidya S, Ghosh K, Shanmukhaiah C, Vundinti BR (2015) Genetic variations of hOCT1 gene and CYP3A4\/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia. Eur J Pharmacol 765:124\u2013130. doi: 10.1016\/j.ejphar.2015.08.034","journal-title":"Eur J Pharmacol"},{"key":"3266_CR39","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.3109\/10428194.2014.893307","volume":"55","author":"J Vine","year":"2014","unstructured":"Vine J, Cohen SB, Ruchlemer R et al (2014) Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. Leuk Lymphoma 55:2525\u20132531. doi: 10.3109\/10428194.2014.893307","journal-title":"Leuk Lymphoma"},{"key":"3266_CR40","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/leu.2010.86","volume":"24","author":"A Bazeos","year":"2010","unstructured":"Bazeos A, Marin D, Reid AG et al (2010) hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 24:1243\u20131245. doi: 10.1038\/leu.2010.86","journal-title":"Leukemia"},{"key":"3266_CR41","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/jhg.2010.98","volume":"55","author":"N Takahashi","year":"2010","unstructured":"Takahashi N, Miura M, Scott SA et al (2010) Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 55:731\u2013737. doi: 10.1038\/jhg.2010.98","journal-title":"J Hum Genet"},{"key":"3266_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2012.066480","volume":"98","author":"S Angelini","year":"2013","unstructured":"Angelini S, Soverini S, Ravegnini G et al (2013) Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 98:193\u2013200. doi: 10.3324\/haematol.2012.066480","journal-title":"Haematologica"},{"key":"3266_CR43","doi-asserted-by":"publisher","first-page":"e51771","DOI":"10.1371\/journal.pone.0051771","volume":"7","author":"O Singh","year":"2012","unstructured":"Singh O, Chan JY, Lin K et al (2012) SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. PLoS One 7:e51771. doi: 10.1371\/journal.pone.0051771","journal-title":"PLoS One"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3266-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T12:29:45Z","timestamp":1498393785000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3266-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,12]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["3266"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3266-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,12]]}}}